Literature DB >> 19481452

Synthesis and evaluation of an acyl-chain unsaturated analog of the Th2 biasing, immunostimulatory glycolipid, OCH.

Geetha Velmourougane1, Ravinder Raju, Gabriel Bricard, Jin S Im, Gurdyal S Besra, Steven A Porcelli, Amy R Howell.   

Abstract

An alpha-galactosyl ceramide (alpha-GalCer) 2 was synthesized and evaluated for its ability to stimulate iNKT-cell proliferation and elicit T-helper cytokines, IL-4 and IFNgamma. Compound 2 combines the acyl chain of the potent, Th2 biasing alpha-GalCer 1 with a sphingoid base of the same length as that found in OCH, which also exhibits Th2 skewing, Such complementation may enhance cytokine bias, which is thought to be important for therapeutic applications of iNKT cell stimulation. Two related alpha-GalCers, 3 and 4, with saturated acyl chains were prepared for comparison.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19481452      PMCID： PMC2743301          DOI： 10.1016/j.bmcl.2009.05.042

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  15 in total

Review 1.  The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy.

Authors:  Karl O A Yu; Steven A Porcelli
Journal:  Immunol Lett       Date:  2005-08-15       Impact factor: 3.685

Review 2.  T cells and NKT cells in the pathogenesis of asthma.

Authors:  Everett H Meyer; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

Review 3.  Harnessing NKT cells for therapeutic applications.

Authors:  V Cerundolo; M Salio
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

Review 4.  CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system.

Authors:  Jennifer L Matsuda; Thierry Mallevaey; James Scott-Browne; Laurent Gapin
Journal:  Curr Opin Immunol       Date:  2008-05-22       Impact factor: 7.486

5.  Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides.

Authors:  Karl O A Yu; Jin S Im; Alberto Molano; Yves Dutronc; Petr A Illarionov; Claire Forestier; Nagatoshi Fujiwara; Isa Arias; Sachiko Miyake; Takashi Yamamura; Young-Tae Chang; Gurdyal S Besra; Steven A Porcelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-18       Impact factor: 11.205

6.  A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

Authors:  Giuseppe Giaccone; Cornelis J A Punt; Yoshitaka Ando; Rita Ruijter; Nobusuke Nishi; Marlies Peters; B Mary E von Blomberg; Rik J Scheper; Hans J J van der Vliet; Alfons J M van den Eertwegh; Marja Roelvink; Jos Beijnen; Heinz Zwierzina; Herbert M Pinedo
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

7.  A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells.

Authors:  K Miyamoto; S Miyake; T Yamamura
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

Review 8.  NKT cells: potential targets for autoimmune disease therapy?

Authors:  K J L Hammond; D I Godfrey
Journal:  Tissue Antigens       Date:  2002-05

Review 9.  CD1-restricted T cells and tumor immunity.

Authors:  J B Swann; J M C Coquet; M J Smyth; D I Godfrey
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

10.  Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice.

Authors:  M Morita; K Motoki; K Akimoto; T Natori; T Sakai; E Sawa; K Yamaji; Y Koezuka; E Kobayashi; H Fukushima
Journal:  J Med Chem       Date:  1995-06-09       Impact factor: 7.446
View more
  9 in total

1.  OCH-mediated shift of Th1 and Th2 cytokines by NKT cells in mice with aplastic anemia.

Authors:  Xiaohong Qiao; Xiaotian Xie; Wei Shi; Jinqing Tang; Yuexia Shao; Fuxing Li
Journal:  Med Oncol       Date:  2015-02-19       Impact factor: 3.064

Review 2.  Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.

Authors:  Wenji Sun; Priyanka B Subrahmanyam; James E East; Tonya J Webb
Journal:  J Interferon Cytokine Res       Date:  2012-10-10       Impact factor: 2.607

3.  In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models.

Authors:  Kun-Hsien Lin; Jian-Jong Liang; Wen-I Huang; Shao-Ying Lin-Chu; Ching-Yao Su; Yi-Ling Lee; Jia-Tsong Jan; Yi-Ling Lin; Yih-Shyun E Cheng; Chi-Huey Wong
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

4.  Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants.

Authors:  Priyanka Subrahmanyam; Tonya J Webb
Journal:  Front Biol (Beijing)       Date:  2012-10-01

5.  Regulation of the actin cytoskeleton by Rho kinase controls antigen presentation by CD1d.

Authors:  Richard M Gallo; Masood A Khan; Jianjian Shi; Reuben Kapur; Lei Wei; Jennifer C Bailey; Jianyun Liu; Randy R Brutkiewicz
Journal:  J Immunol       Date:  2012-07-13       Impact factor: 5.422

6.  New CD1d agonists: synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides.

Authors:  Peter J Jervis; Lisa M Graham; Erin L Foster; Liam R Cox; Steven A Porcelli; Gurdyal S Besra
Journal:  Bioorg Med Chem Lett       Date:  2012-05-09       Impact factor: 2.823

Review 7.  Stimulation of natural killer T cells by glycolipids.

Authors:  Brian L Anderson; Luc Teyton; Albert Bendelac; Paul B Savage
Journal:  Molecules       Date:  2013-12-16       Impact factor: 4.411

8.  Relationships between Th1 or Th2 iNKT cell activity and structures of CD1d-antigen complexes: meta-analysis of CD1d-glycolipids dynamics simulations.

Authors:  Xavier Laurent; Nicolas Renault; Amaury Farce; Philippe Chavatte; Eric Hénon
Journal:  PLoS Comput Biol       Date:  2014-11-06       Impact factor: 4.475

9.  Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice.

Authors:  Junfei Wei; Venkatesh L Hegde; Ananta V Yanamandra; Madison P O'Hara; Brian Keegan; Kathryn M Jones; Ulrich Strych; Maria Elena Bottazzi; Bin Zhan; K Jagannadha Sastry; Peter J Hotez
Journal:  Front Immunol       Date:  2022-02-07       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.